Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
To characterize the pharmacokinetics and safety of regorafenib in cancer subjects with severe
renal impairment when compared to the Control group (cancer subjects with normal or mildly
impaired renal function)